Opioid Use Disorder and Co-Occurring Mental Health: Why Residential Treatment Is Often the Right Level of Care
Published by Starbridge Recovery | California Dual Diagnosis Residential Treatment
Opioid use disorder carries the highest mortality risk of any substance use disorder in the United States. It is also among the most highly comorbid — the conditions that co-occur with OUD are not incidental. They are central to its development, maintenance, and treatment.
Understanding why residential treatment is often the clinically indicated level of care for patients with OUD and co-occurring mental health conditions — and what effective residential treatment for this population looks like — is essential for any clinician, case manager, or family navigating a placement decision.
The Scale of OUD and Co-Occurring Mental Health
SAMHSA's 2024 NSDUH data identified approximately 4.8 million people in the United States with a past-year opioid use disorder. Among adults presenting at health centers with OUD, the two most frequently documented co-occurring mental health conditions were mood disorders and anxiety disorders. Research from the CDC further finds that OUD and co-occurring psychiatric conditions significantly increase healthcare utilization, treatment dropout, and mortality.
A research study examining co-occurring psychiatric conditions in people with OUD found that anxiety (38.2%), depression (33.1%), ADHD (14.6%), bipolar disorder (5.1%), and PTSD (4.5%) were among the most prevalent psychiatric diagnoses. The same study found that the presence of co-occurring conditions was associated with worse treatment retention — a finding that underscores the clinical importance of treating both conditions simultaneously rather than focusing narrowly on the opioid use.
Despite the prevalence of OUD and the availability of evidence-based treatment, only 17 percent of people with OUD received medications for OUD (MOUD) in the past year. The treatment gap is not explained by lack of clinical options — it is explained by stigma, access barriers, and treatment systems that are not equipped to serve the complexity of this population.
Why OUD Rarely Travels Alone
The relationship between opioid use and mental health conditions is deeply bidirectional:
Opioids are powerful anxiolytics and mood modulators. For individuals with untreated or undertreated anxiety, depression, or trauma, opioids provide a degree of symptom relief that few other substances can match — warmth, calm, analgesia for emotional as well as physical pain. The pharmacological logic of opioid misuse in the context of psychiatric comorbidity is not difficult to understand. It does not make it less dangerous, but understanding it changes how treatment must be designed.
Opioid use worsens underlying psychiatric conditions over time. The neuroadaptation that produces physical dependence also dysregulates the stress response system, the emotional processing circuits, and the reward pathway in ways that deepen depression, amplify anxiety, and increase trauma reactivity. Protracted abstinence syndrome — the weeks and months of subacute neurological adjustment that follow opioid discontinuation — includes dysphoria, anxiety, sleep disruption, and anhedonia that can be clinically indistinguishable from primary depressive or anxiety disorders.
Trauma and opioid use disorder are deeply entangled. Research consistently identifies adverse childhood experiences (ACEs), sexual trauma, physical trauma, and prolonged psychosocial adversity as significant risk factors for OUD. For many individuals, opioid use begins as a response to untreated trauma — and relapse, when it occurs, is often precipitated by trauma triggers rather than drug-specific cravings.
When Outpatient Treatment Is Not Enough
The ASAM Criteria provide the clinical framework for determining when residential treatment is indicated for OUD. Several ASAM dimensions specifically point toward residential placement for patients with co-occurring mental health conditions:
Dimension 3 (Emotional, Behavioral, and Cognitive Conditions): When a co-occurring psychiatric condition is of sufficient severity that it requires daily clinical monitoring, psychiatric oversight, and integrated treatment that cannot be adequately delivered in an outpatient setting.
Dimension 5 (Relapse, Continued Use, and Continued Problem Potential): When the patient's history of relapse, the severity of opioid use, and environmental triggers suggest that outpatient-level interventions have been insufficient or are insufficient to maintain safety and engagement.
Dimension 6 (Recovery and Living Environment): When the patient's home or community environment includes active substance use, unsafe relationships, housing instability, or other environmental factors that make outpatient engagement clinically untenable.
In practice, many patients with OUD and co-occurring mental health conditions have been in and out of outpatient treatment without sustained benefit — not because they lack motivation or intelligence, but because outpatient programming did not provide the clinical intensity, the psychiatric integration, or the environmental separation from triggers that their clinical picture required.
Residential treatment provides what outpatient cannot: 24-hour clinical support, removal from the environment in which the use was occurring, daily therapeutic programming, integrated psychiatric care, and the time and structure necessary to begin the neurological and psychological stabilization from which recovery can be built.
What Effective Residential OUD Treatment Looks Like
For patients with OUD and co-occurring mental health conditions, effective residential treatment requires:
MAT as a clinical standard, not an exception. Buprenorphine, methadone, and naltrexone are first-line treatments for OUD. A residential program that does not support MAT is not providing evidence-based care for OUD. Programs that require patients to discontinue MOUD at admission are creating clinical risk that the evidence does not support.
Integrated psychiatric care. The co-occurring mental health conditions that drove opioid use — anxiety, depression, PTSD, mood disorders — must be assessed, diagnosed, and treated as primary clinical targets, not as secondary concerns to be addressed after sobriety is established.
Trauma-informed programming. Given the high prevalence of trauma in the OUD population, residential programming must be grounded in trauma-informed care principles — physical and emotional safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and sensitivity to cultural, historical, and gender issues.
Relapse prevention and coping skills. Cognitive-behavioral relapse prevention, emotional regulation skills (DBT), and coping skills for managing anxiety, depression, and trauma triggers are essential components of programming for this population.
A robust discharge plan that includes MAT continuation. Patients leaving residential OUD treatment without a confirmed MAT provider, a scheduled appointment, and a medication in hand are at elevated overdose risk. The discharge plan for every OUD patient must address MOUD continuity explicitly.
Starbridge and the OUD Population
Starbridge Recovery serves adults with opioid use disorder and co-occurring mental health conditions as a core part of our clinical population. We accept patients on MAT, provide integrated psychiatric management, and offer evidence-based dual diagnosis programming designed for the clinical complexity this population presents.
We work with referral sources across the country and accept out-of-state patients for whom the distance from their home environment is itself a clinical asset — removing them from the triggers, relationships, and environments that have sustained their opioid use while providing the residential structure and clinical depth to build sustainable recovery.
Starbridge Recovery is a DHCS-licensed, Joint Commission-accredited dual diagnosis residential program in California. To discuss a referral or clinical placement for a patient with opioid use disorder and co-occurring mental health conditions, [contact our admissions team].
References
- CDC. (2024). Health Center Visits by Adults With Opioid Use Disorder, United States, 2023. https://www.cdc.gov/nchs/products/databriefs/db544.htm
- SAMHSA. (2024). 2024 NSDUH Annual Report. https://www.samhsa.gov/data/
- Morse, S. & Bride, B.E. (2017). Decrease in Healthcare Utilization Following Residential Integrated Treatment for Co-Occurring Disorders. Healthcare, 5(3). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618182/
- Liu, L., et al. (2025). Impact of Co-Occurring Psychiatric Comorbidities on Outcomes in Adolescents and Young Adults with OUD. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12114498/
- ASAM. (2023). The ASAM Criteria, Fourth Edition. https://www.asam.org/asam-criteria